Algernon Pharmaceuticals Provides Update on its Planned Phase II Clinical Trial
November 25, 2019 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, B.C., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development...
Algernon Announces Closing of $2.07 Million Prospectus Offering of Units
November 01, 2019 09:31 ET
|
Algernon Pharmaceuticals
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc....
Algernon Announces Pricing of Prospectus Offering
September 06, 2019 07:00 ET
|
Algernon Pharmaceuticals
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc....
Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent Anti-Fibrotic Activity in NASH and CKD Studies
July 31, 2019 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 31, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis in a Recent Idiopathic Pulmonary Fibrosis Study by 56%
July 29, 2019 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 29, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Algernon Pharmaceuticals Announces Short Form Prospectus Unit Offering
July 04, 2019 07:00 ET
|
Algernon Pharmaceuticals
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British...
Algernon Pharmaceuticals Begins Trading on The CSE Under The Symbol AGN
February 19, 2019 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce...
Breathtec Announces Name Change to Algernon Pharmaceuticals
February 14, 2019 07:00 ET
|
Breathtec Biomedical Inc.
New corporate identity aligned with the Company's main strategy to be a global leader in the treatment of liver disease (NASH), chronic kidney disease and inflammatory bowel disease. The company's...